Electrochemical Carbamazepine Aptasensor for Therapeutic Drug Monitoring at the Point of Care

Point-of-Care Drug Testing

This comprehensive review explores the advancements, applications, and challenges of Point-of-Care Testing (POCT) for drug detection. It covers the evolution of drug-testing technologies, including immunoassays and biosensors, and highlights their impact in clinical, legal, and workplace settings. The article discusses the benefits of POCT, such as rapid results, accessibility, and cost-effectiveness, alongside challenges like accuracy, regulatory concerns, and standardization. Future innovations, including integration with digital health and next-generation devices, are also explored, underscoring POCT's potential to revolutionize drug testing across various sectors.

Recent Advances in Electrochemical Aptasensors for Detection of Clinical and Veterinary Drugs

Nowadays, aptamer-based biosensors and electrochemical measurements represent one of the efficient tools for the detection of drugs in both medical and veterinary. Precise trace values analysis of chemicals, especially drugs, plays a crucial role in food and therapeutic safety evaluations that are often time-consuming and costly. Ultimately, accurate determination of therapeutic medications like antibiotics in food, environmental resources, and biological matrices is very important for protecting public health and drug monitoring (TDM) for effective treatment. This review highlights recent advancements in electrochemical aptasensors as an innovative approach offering high sensitivity, specificity, and rapid detection of clinical and veterinary drugs at lower costs. We provide a comprehensive overview of the advancements and discuss the challenges and prospects of electrochemical aptasensing in drug residue detection across various samples.

A high-performance aptasensing interface based on pseudo-AuNBs@Ti3C2Tx MXene nanocomposite for non-invasive measurement of carbamazepine in human biofluids

For the first time, a novel aptasensing interface based on smart integration of pseudo-gold nanobons (AuNBs) and Ti3C2Tx MXene is introduced for high selective detection of carbamazepine (CBZ). The large specific surface area achieved from the proposed nanocomposite increases the targeted immobilization of the Apt sequence on the surface via AuNBs as the linkage. It embeds a high-performance grafting platform for trapping CBZ with high sensitivity and accuracy in human biofluids and pharmaceutical formulations. The molecular dynamic (MD) simulation method that exhibits how the Apt binds to CBZ in a conformation-switching assay format from a molecular view is a valid certification for the interaction of CBZ on the developed aptasensing interface. The aptasensor measured CBZ from 1 fM to 100 nM with a superior detection limit (LOD) value of 330 aM compared with other reported CBZ sensors. Due to using biocompatible and non-toxic compounds, consuming low energy and chemicals the greenness of the proposed strategy has been certified by the international scoring system.

Overview of therapeutic drug monitoring and clinical practice

With the rapid development of clinical pharmacy in China, therapeutic drug monitoring (TDM) has become an essential tool for guiding rational clinical drug use and is widely concerned. TDM is a tool that combines pharmacokinetic and pharmacodynamic knowledge to optimize personalized drug therapy, which can improve treatment outcomes, reduce drug-drug toxicity, and avoid the risk of developing drug resistance. To effectively implement TDM, accurate and sophisticated analytical methods are required. By researching the literature published in recent years, we summarize the types of commonly monitored drugs, therapeutic windows, and clinical assays and track the trends and hot spots of therapeutic drug monitoring. The purpose is to provide guidelines for clinical blood drug concentration monitoring, to implement individualized drug delivery programs better, to ensure the rational use of drugs for patients, and to provide a reference for the group to carry out related topics in the future.

Aptamer-based rapid diagnosis for point-of-care application

Aptasensors have attracted considerable interest and widespread application in point-of-care testing worldwide. One of the biggest challenges of a point-of-care (POC) is the reduction of treatment time compared to central facilities that diagnose and monitor the applications. Over the past decades, biosensors have been introduced that offer more reliable, cost-effective, and accurate detection methods. Aptamer-based biosensors have unprecedented advantages over biosensors that use natural receptors such as antibodies and enzymes. In the current epidemic, point-of-care testing (POCT) is advantageous because it is easy to use, more accessible, faster to detect, and has high accuracy and sensitivity, reducing the burden of testing on healthcare systems. POCT is beneficial for daily epidemic control as well as early detection and treatment. This review provides detailed information on the various design strategies and virus detection methods using aptamer-based sensors. In addition, we discussed the importance of different aptamers and their detection principles. Aptasensors with higher sensitivity, specificity, and flexibility are critically discussed to establish simple, cost-effective, and rapid detection methods. POC-based aptasensors' diagnostic applications are classified and summarised based on infectious and infectious diseases. Finally, the design factors to be considered are outlined to meet the future of rapid POC-based sensors.